Clinical Trial Update: PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

View source ↗

Summary

A completed multicancer registry study (PREFER) assessing the prevalence of actionable biomarkers and driver mutations across advanced cancers to address dispar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Endometrial Cancer
• Lung Cancer
• Melanoma
• Ovarian Cancer
• Pancreatic Cancer
• Prostate Cancer

Snippet

Sponsor: Labcorp Corporation of America Holdings, Inc | Conditions: Lung Cancer, Ovarian Cancer | Status: COMPLETED